Philippines Beaver Tamesis, Managing Director at MSD Philippines, discusses the company’s impressive growth in recent years as well as their expanding portfolio. Additionally, he discusses his work to foster engagement and motivation throughout the MSD affiliate in the country. When we first met you in 2013 you were only a few…
Pharma Olaf Weppner, General Manager of AbbVie Switzerland, highlights AbbVie’s intended foray into oncology, the importance of immunology to the group, the challenges and opportunities of the Swiss market and his own motivations for working in the industry. Mr. Weppner, you were appointed General Manager of AbbVie Switzerland less than a…
Ireland Julie O’Neill, Alexion’s EVP for Global Operations highlights Alexion’s establishment of its Global Supply Chain headquarters in Dublin, Ireland, its investment in Athlone, her thoughts on the opportunities and challenges in the Irish pharmaceutical landscape, and her vision for Alexion. Alexion first established a manufacturing presence in Dublin, Ireland in…
Innovation Professor Mark Ferguson, Director General of Science Foundation Ireland and Chief Scientific Advisor to the Government of Ireland, highlights Ireland’s recent spectacular success in fostering research and innovation; the government’s strategy to further promote Irish science, Innovation 2020; the priority of building academia-industry partnerships; and his mission to turn Ireland…
Pharma Raul Vivar, recently appointed GM of Eisai Mexico, describes the main achievements of the Japanese company in Mexico, the challenges that innovative companies face entering the Mexican market, and the development path he will follow in order to foster growth. You took over the helm of the Mexican affiliate of…
Pharma Ireland is home to Recordati’s external supply operations and global in-licensing teams, alongside the API facility for one of the company’s most prolific products; Director Michael Kilkelly discusses the advantages of running such operations in Ireland, beyond the many financial incentives. In your opinion, why is Ireland such an attractive…
Philippines Peter Kompalla, executive director of the German-Philippine Chamber of Commerce and Industry, discusses the chamber’s activities in the country working to promote German-Filipino trade, their extensive and growing advocacy efforts on behalf of their members, as well how good business values help to bond German companies of all sizes operating in the…
Health Raúl Riquelme Cacho, president of the health commission of the Confederation of Industrial Chambers of the United Mexican States (CONCAMIN), reveals the recent alignment of CONCAMIN, which stands as the most important industry organization of Mexico, with the main pharmaceutical associations, and discusses the cross-sector objectives that unite these stakeholders:…
Pharma Efrén Ocampo, CEO of the Mexican pharmaceutical group Neolpharma, details the strategic thinking that has fostered the emergence of one of the most prominent healthcare groups in Mexico and the challenges and opportunities that lie ahead in Mexico and abroad. Neolpharma Group encompasses five manufacturing companies and 14 other service…
Ireland Barry Heavey, Head of Life Sciences at IDA Ireland, Ireland’s inward investment promotion agency, discusses IDA’s focus on acting as a catalyst for B2B collaboration in converging industries like connective health solutions and innovative drug delivery devices, their focus on advanced manufacturing, and his mission to make IDA Ireland the…
Pharma Tuomo Pätsi, President of the EMEA region for Celgene, talks about marking the tenth anniversary of Switzerland as Celgene´s EMEA headquarters; reveals how their workforce has increased from a handful of individuals in 2006 to 700 in Switzerland and 2,300 across Europe today; and how Celgene’s continuous R&D investment distinguishes…
Pharma Hetero, the global API leader, has consolidated its position as the partner of choice of the pharmaceutical industry in Mexico, with a portfolio of more than 300 APIs. GM Gurulinga Konanuris is piloting entry into the B2C market, with upcoming launches of biosimilars, oncology and HIV treatments. Hetero is also investing…
See our Cookie Privacy Policy Here
